Debate over Nanobacteria contamination in Vaccines

Another debate in viral vaccines: nanobacterial contaminationhttp://www.asmusa.org/pcsrc/gm2001/33749.htm
101st General Meeting of the American Society for Microbiology
May 20-24, 2001, Orlando, Florida
For more information on any presentation at the 101st General Meeting conta=
ct Jim Sliwa, ASM Communications at jsliwa@asmusa.org.(Session 078/Y , Paper Y-3)
Neva Ciftcioglu
University of Kuopio
Kuopio,
Finland
35817163054
neva.ciftcioglu@uku.fi
Vaccines are an indispensable weapon in the battle to prevent disease, both=
in humans and animals. Provision and protection of the vaccine supply is so=
essential that no possible pathogen is beyond suspicion. So it is with nano=
bacteria (NB), a potential infectious agent so new that science is still deb=
ating its existence as a "living organism". We analysed 6 veterinary vaccine=
s and 3 inactivated human polio vaccines produced in cell culture for NB. We=
report that 3 of 6 European veterinary vaccines contained NB. Of the 3 dist=
inct lots of polio vaccine from European manufacturers, 2 lots from manufact=
urer-1 were NB-positive and 1 lot from manufacturer-2 was NB-negative. These=
results suggest that not all lots of vaccine contain detectable NB. The pub=
lic health risk, if any, from nanobacteria is yet to be defined, but nanobac=
teria have been found in kidney stones, liver and kidney cyst fluids, and im=
plicated in kidney stone formation.
In the early 1990's, Drs. Olavi Kajander and Neva Ciftcioglu, University of=
Kuopio, Finland discovered a minute self replicating agent, which was named=
"nanobacteria", in fetal bovine serum (FBS) that mediates mineral (calcium =
phosphate) formation under conditions found in blood and urine. NB was subse=
quently found to contaminate cell cultures widely used in research and to pa=
ss through filters commonly used to sterilize vaccines. Several vaccines are=
produced in mammalian cell cultures that were initially or are currently cu=
ltured in media supplemented with FBS. Thus, the question arose, "Could the =
NB found in some batches of FBS contaminate some vaccines"?
To detect nanobacteria in these 9 vaccines, the Kuopio University team cult=
ured the vaccines in routine tissue culture medium known by prior testing to=
be free of NB and examined the original vaccines and cultured vaccines by e=
lectron microscopy, and immunologic tests for NB antigens (immunofluorescent=
staining, dot blot assay and ELISA). NB were found 3 of 6 vet vaccine produ=
cts and 2 of 3 human vaccine products prepared using FBS. A second question =
arose, "Even if NB are present in the culture broth, why were they not remov=
ed during the purification and sterilizing steps of vaccine production"?
Cell culture mediated viral vaccine production requires the use of cells to=
propagate large amounts of virus, which is then filtered to remove contamin=
ates and cells present in the propagation step. The viruses passing through =
the filters are then further processed and inactivated prior to use. NB are =
in the same size range as certain large viruses, and may adhere to viruses t=
hus escaping purification steps using filtration. NB are also resistant to m=
any disinfecting chemicals and antibiotics. NB can exist intracellularly and=
grow in the absence of FBS. At this time it is not known if FBS added to th=
e production cell lines or NB in the cells lines themselves are the source o=
f NB contamination in these cases.
The Center for Biologics Evaluation and Research (CBER) and the U.S. Food a=
nd Drug Administration (FDA) learned earlier this year that some vaccines we=
re manufactured with bovine–derived materials obtained from countries where =
bovine spongiform encephalopathy (BSE; mad cow disease) is prevalent or wher=
e a substantial risk for BSE exists. Creutzfeldt-Jakob disease (vCJD), the h=
uman equivalent of BSE, has been attributed to, among other possibilities, e=
ating beef products from cattle infected with the prion agent of BSE. Althou=
gh there is no evidence to date that cases of vCJD are related to the use of=
vaccines, interestingly a vaccine lot was withdrawn because of being expose=
d to FBS from the country where high risk for this prion disease exists.
The study summarised in the first paragraph will be presented in the 101st =
ASM Meeting in Orlando in May 21, 2001 (1.00-2.30pm). The Kuopio team's mess=
age to the scientific society in this presentation will be: More research is=
needed to understand nanobacteria and their role in human and animal diseas=
es. To err on the side of safety is no vice; just as prions and viruses were=
viewed with scepticism before they were completely characterised, so concep=
ts of nanobacteria (and the scientists who study them) will be knocked aroun=
d until more is known about NB. Vaccines should be regarded as safe and esse=
ntial to human health in the modern age until they are proven otherwise.
Related Literature:
NB have been linked to kidney stones (Ciftcioglu et al., Kidney Internation=
al 56:1893-8,1999), as a kidney stone causative agent (Garcia Cuerpo et al.,=
Arch Esp Urol 53:291-303, 2000), and in polycystic kidney disease (Hjelle e=
t al, Kidney International 57: 2360-2374, 2000).
For a recent review of nanobacteria, (Kajander, Ciftcioglu, Miller-Hjelle, =
Hjelle. Current Opinions in Nephrology and Hypertension 2001 in press).

 FAIR USE NOTICE  
  This site may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner - or on which copyright has expired. We are making such material available in our efforts to advance understanding of environmental, political, human rights, health, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.